Artemis Medicare Services Limited Overview
Artemis Medicare Services is a promoter-backed, quaternary-care hospital operator. Its economics are still dominated by one asset: the JCI- and NABH-accredited Artemis Hospital in Gurugram. That hospital has 700 beds of built capacity and about 544 operational beds, and it produced roughly 97% of consolidated revenue in Q1 FY27. The Company competes in the crowded Delhi-NCR tertiary-care market against much larger peers: Medanta, Fortis, Max and Apollo. Its differentiation rests on a high-acuity case mix (oncology, neurosciences, cardiac sciences, transplants), on management's claim of the highest ARPOB in NCR (about INR 85,690 in Q1 FY27), and on an unusually large international-patient franchise (27–34% of Gurugram revenue). Artemis is now moving from a single-flagship model to a multi-site network. Its tools are brownfield FAR-led expansion at Gurugram, an asset-light Medical Services Agreement model (Raipur, opened July 2026; VIMHANS South Delhi, targeted for FY29) and a proposed INR 700 crore equity raise. The stated target is 2,000–2,300 beds by 2029.
What the Company does
Artemis Medicare Services owns, operates and manages multi-specialty and super-specialty hospitals. Its activity is concentrated in the Delhi National Capital Region (NCR). It is now extending into Central India (Raipur, Chhattisgarh), with management/operations arrangements in Mauritius. Company boilerplate in the Q3 FY26 press release says Artemis operates 800+ beds, mainly in Delhi-NCR, including the 700+ bed flagship Gurugram hospital. It also cites cardiac centres run with Philips under the Artemis Cardiac Care brand, and an overseas presence in Mauritius through an operations arrangement (Q3 FY26 press release, 2 Feb 2026).
Screener's company description, which is derived from Company disclosures, characterises the business as running multi-specialty hospitals in Haryana under the Artemis Hospitals brand. It lists cardiology, oncology, orthopaedics, neurology, nephrology, gastroenterology and critical care among the specialties.
Business and revenue model
| Revenue model component | Description | Disclosure status |
|---|---|---|
| In-patient services (IP) | Bed-day, procedure, surgical, ICU, pharmacy and consumables billed per admission. This is the core of ARPOB. Q1 FY27 Gurugram IP volume was 9,181. | Q1 FY27 investor materials (via Multibagg summary) |
| Out-patient services (OP) | Consultations, diagnostics, day-care | OP split not publicly disclosed in retrieved sources |
| International patients (medical value travel) | 27% (Q1 FY27) to 34% (Q3 FY26) of Gurugram revenue; Q1 FY27 international revenue was INR 76.51 crore | Q1 FY27 and Q3 FY26 releases |
| Payor channels | Q1 FY27 Gurugram mix: international 27%, insured 33%, domestic cash 23%, government schemes 17% | Q1 FY27 investor materials |
| Asset-light hospital management (MSA / long-term agreements) | Artemis brands and operates hospitals owned by third parties (VIMHANS South Delhi MSA, Feb 2026). Raipur Artemis Shanti operates under a long-term agreement. Mauritius is an operations arrangement. | NSE intimation 20 Feb 2026; Sahi summary of Q1 FY27 filing |
| Allied / satellite formats | Artemis Lite (neighbourhood multi-specialty), Daffodils by Artemis (women & child), Artemis Cardiac Care (JV with Philips), Artemis Solace (described by AlphaStreet as one of the diversification models; scope not detailed in sources) | IFC release Apr 2024; AlphaStreet; CARE 2023 |
There is no material product, subscription or licensing revenue. Management and brand fees from MSA arrangements are an emerging and still undisclosed component.
Value-chain position, customers and end-markets
Artemis sits at the tertiary and quaternary end of the provider chain. It receives referrals from primary and secondary providers, from international facilitators and from insurers and TPAs. Its customers are:
-
Domestic self-pay patients.
-
Privately insured patients (via insurers and TPAs).
-
Corporate employer programmes.
-
Government scheme beneficiaries (central and state schemes, contributing 17% of Q1 FY27 Gurugram revenue).
-
International patients. Management cited resilience despite West Asia geopolitical tension in Q1 FY27 (ScanX summary of Q1 FY27 call).
The specialty mix is weighted to high-acuity care. Oncology contributed 19% and neurosciences 15% of the revenue mix (AlphaStreet Q3 FY26 summary).
Independent characterisation
Artemis is best understood as a single-asset quaternary hospital with a regional-network option attached. Its quality metrics (ARPOB, international mix, accreditation) are competitive with NCR's top tier. Its scale is roughly one-tenth of the large listed chains. FY26 consolidated PAT was about INR 104 crore, against INR 1,000–1,950 crore for Apollo, Max and Fortis (Fyers peer snapshot). The investment case over FY27–FY29 rests on three things: utilisation (lifting Gurugram occupancy from about 65% to 70%+), FAR-led brownfield capacity at near-zero land cost, and execution of capital-light MSAs. Rising other-income and falling interest costs flatter recent PAT growth. The core operating improvement is real, though: EBITDA rose 27.9% YoY on 12.7% revenue growth in Q1 FY27.
Strategy
Stated strategic themes (paraphrased from FY26 calls and releases)
-
Scale from about 800 to 2,000–2,300 beds by 2029. Management described this as moving Artemis from a 700–800-bed group to roughly 2,300 beds (Q3 FY26 call, 3 Feb 2026). Sharekhan cites an earlier target of 1,700+ beds by FY29.
-
Sweat the flagship first. The plan is to lift Gurugram occupancy to about 70%, and to commission an extra ~100 beds only once occupancy reaches 70% (Q4 FY26 call notes). Management projected about 70% by Q2 FY27 and 68–70% for the year.
-
Near-zero-cost brownfield. The IGBC Platinum certification adds 15% FAR (100–125 beds at no land cost). Purchased FAR up to 2.15 would add about 200 more beds, taking Gurugram to 950–1,000 beds.
-
Capital-light network expansion through MSAs and long-term agreements. Examples are Raipur (operational) and VIMHANS South Delhi (650+ beds). Further projects are "in the funnel".
-
Protect pricing and case mix. Management guides 4–6% annual ARPOB growth and points to quaternary programmes such as heart and lung transplant and oncology.
-
Medical value travel. The international franchise is to be sustained at 27–34% of flagship revenue.
-
Digital and clinical technology. AI-assisted triage has been deployed across hospitals.
Initiatives register (last 24 months)
| Date | Initiative | Type | Targets / detail |
|---|---|---|---|
| Apr–May 2024 | IFC INR 330 crore CCD | Capital / strategic investor | Bed capacity, new specialties, cardiac centres in Tier-2/3 cities |
| FY25 | ABTP physiotherapy partnership | Partnership | Tech-enabled physio |
| FY25–FY26 | Gurugram third tower (700 beds) | Brownfield | Ramp to 70% occupancy |
| FY26 | IGBC Platinum certification | ESG / capacity | +15% FAR, about 100–125 beds |
| FY26 | AI-assisted triage | Digital | Shorter wait times |
| Feb 2026 | INR 700 crore fund-raise approval | Capital | Funds new hospitals, Gurugram organic growth, VIMHANS beds; target net debt of INR 250–280 crore (Angel One) |
| 20 Feb 2026 | VIMHANS Artemis Hospital MSA | Asset-light expansion | 450 beds by FY29, then 650+ |
| 2,026 | Heart & Lung Transplant Centre | Clinical | North India thoracic transplant hub |
| 9 Jul 2026 | Artemis Shanti Hospital, Raipur | Greenfield / long-term agreement | Breakeven 15–24 months |
| Jun–Jul 2026 | Fund-raise of up to INR 700 crore re-approved (Board 18 Jun; postal ballot 20 Jul) | Capital | QIP/preferential; analysts (Analytics Insight) link part of it to acquisitions |
| FY26 | Mauritius Cascavelle (110 beds) | International O&M | Announced for FY26 |
Medium-term guidance (management, FY27)
| Item | Guidance | Source |
|---|---|---|
| Gurugram occupancy | About 70% by Q2 FY27; 68–70% by end-FY27 | Q1 FY27 and Q4 FY26 calls |
| ARPOB growth | 4–6% YoY sustainable; 4–5% expected near term | Q4 FY26 and Q1 FY27 calls |
| Absolute EBITDA | Continued expansion in FY27 | Q4 FY26 call |
| Raipur breakeven | 18–24 months from launch (some summaries say 15–18 months to EBITDA-positive) | Q4 FY26 call; Sahi |
| Bed capacity | 2,000–2,300 beds by 2029 | Q3 FY26 call |
| VIMHANS | Phase 1 (~450 beds) by FY29 | NSE intimation |
Explicit revenue or margin targets in numeric form for FY27–FY29 were not publicly disclosed.
Products & Services
Artemis' "products" are clinical service lines, hospital formats and enabling programmes. Pricing is per-episode, under tariff schedules that are not published as company-wide disclosures. Third-party medical-tourism listings are cited where they exist and flagged as such.
Centres of Excellence (Gurugram flagship)
| Centre | Scope / capabilities | Target customer | Notes / flagship offerings |
|---|---|---|---|
| Artemis Heart Centre (incl. Artemis Parmanand Heart Centre) | Interventional cardiology, cardiac surgery, electrophysiology, structural heart | Domestic and international cardiac patients | Third-party listing (Bookimed) shows heart valve replacement at about USD 10,225–12,270 (not Company-verified) |
| Heart & Lung Transplant Centre | Heart, lung and combined heart-lung transplants; mechanical circulatory support | North India transplant candidates; insurer and government-scheme tie-ups being pursued | Launched 2026 with Dr. Sandeep Attawar. Positioned as North India's integrated thoracic transplant hub; follows ISHLT guidelines and reports to the Indian Heart & Lung Transplant Registry; paediatric transplants planned |
| Artemis Cancer Centre | Medical, surgical and radiation oncology; adult and paediatric | High-acuity oncology, international patients | Oncology about 19% of revenue mix |
| Artemis Neurosciences Centre (incl. CyberKnife centre) | Neurosurgery, neurology, stereotactic radiosurgery | Complex neuro cases | Neurosciences about 15% of revenue mix |
| Artemis Organ Transplant Centre | Liver, kidney, pancreas, bone-marrow (autologous/allogeneic), cornea | Transplant patients, international | Third-party sources describe Artemis as Haryana's first licensed renal transplant centre (historical claim, not re-verified) |
| Joint Replacement & Orthopaedics | Arthroplasty, sports medicine, spine | Domestic and international | ABTP physiotherapy partnership supports rehab |
| Minimally Invasive & Bariatric Surgery | Laparoscopic, robotic-assisted (platform not disclosed), bariatric | Elective surgical | — |
| Gastrosciences | GI medicine, hepatology, GI surgery | — | — |
| Critical Care & Pulmonology | ICU, pulmonology | — | — |
| Women & Child Centre | Obstetrics, gynaecology, neonatology, paediatrics | Families | Complemented by Daffodils |
| Emergency & Trauma Centre | 24x7 emergency, trauma | Catchment | — |
| Dermatology, Cosmetology & Plastic Surgery | Aesthetic and reconstructive | Self-pay | — |
| Pain Medicine & Palliative Care | Pain interventions, palliative | Chronic / oncology | — |
Source for the centre list: Artemis organisational descriptions reproduced on third-party profiles (Prospeo) and medical-tourism listings. These match the website's Centres of Excellence. Launch years for individual centres are not publicly disclosed, except the 2026 Heart & Lung Transplant Centre.
Hospital formats and brands
| Brand / format | Description | Locations | Launch | Status |
|---|---|---|---|---|
| Artemis Hospital (flagship) | JCI- and NABH-accredited quaternary super-specialty | Sector 51, Gurugram | 2,007 | 700-bed capacity (third tower); 544 operational beds in Q1 FY27 |
| Artemis Lite | Neighbourhood multi-specialty hospitals | NFC (Delhi); Sector 82A (Gurugram) | c. FY23 | Operating |
| Daffodils by Artemis | Luxury women & child hospitals | Sector 40 (Gurugram); East of Kailash (Delhi) | c. FY23 | Operating |
| Artemis Cardiac Care | Cardiac centres in Tier-2/3 cities, JV with Philips | Seven centres (2024); Chennai closed Jan 2025 | c. FY23 | Operating |
| Artemis Solace | Listed by AlphaStreet among diversification models | — | — | Scope not publicly detailed |
| Artemis Shanti Hospital | 300+ beds, 50+ specialties, 11 Centres of Excellence | Devendra Nagar, Raipur | 9 Jul 2026 | Ramp-up; breakeven guided at 15–24 months |
| VIMHANS Artemis Hospital | 650+ bed super-specialty under MSA with VIMHANS | Nehru Nagar, South Delhi | Target FY29 (phase 1, ~450 beds) | Construction phase |
| Artemis Curepipe Hospital | 80-bed hospital | Curepipe, Mauritius | FY24 | Operating (operations arrangement) |
| Artemis Cascavelle Hospital | 110-bed hospital | Cascavelle, Mauritius | Announced for FY26 | Opening status not confirmed in retrieved sources |
| OPTIC Clinic | Medical Dialogues reports Artemis launched its "first OPTIC Clinic"; scope not detailed | — | 2,026 | Not detailed |
Enabling and service programmes
| Programme | Description | Year |
|---|---|---|
| International patient services | Facilitation, travel and visa assistance; 27–34% of Gurugram revenue | Ongoing |
| AI-assisted triage | Implemented across hospitals in FY26; management says it cut wait times | FY26 (Q4 FY26 call) |
| ABTP physiotherapy | Technology-enabled sports and rehab physiotherapy with Abhinav Bindra Targeting Performance | FY25 |
| Green building (IGBC Platinum) | Gurugram campus certification; unlocks 15% additional FAR | FY26 |
Financial Narrative
Primary sources:
-
FY24 and FY25: Directors' Report FY25.
-
FY26: Q4 FY26 / FY26 press release and integrated filing.
-
FY22–FY23 and line items not in releases: StockAnalysis (S&P-sourced standardisation of filings), converted from INR million to INR crore.
-
"Gross profit" uses the aggregator's cost-of-revenue classification; it is not a Company-reported metric.
-
All figures are consolidated unless labelled standalone.
Income statement (consolidated, INR crore)
Notes:
-
The standalone PBT for those years comes from Screener's 13-column row (assigned Mar-14 to Mar-25 plus TTM) and is approximate.
-
FY2026 PBT of INR 139.18 crore and net profit of INR 103.62 crore are from the Fyers summary of filings. ScanX reports FY26 net profit of INR 103.72 crore (+26.2%), so the two sources differ marginally.
-
For reference, reported quarterly diluted EPS was INR 1.98 in Q1 FY27 (+46.7%) and INR 1.90 in Q4 FY26.
-
FY26 DPS is the final dividend of INR 0.45 approved at the 22nd AGM (record date 10 Jul 2026). FY24–FY25 DPS is implied by the aggregator's "0% dividend growth" and the 0.17% yield.
EBITDA
Notes:
-
FY26 consolidated EBITDA of INR 21,801 lakh is from the FY26 press release as reproduced by Indian Pharma Post. It is consistent with the reported 9M FY26 EBITDA margin of 20.2% plus Q4 EBITDA of INR 59.38 crore.
-
Quarterly back-calculation suggests FY25 consolidated EBITDA of roughly INR 175–185 crore, which conflicts with Screener's standalone INR 150 crore. That figure may be stale or computed on a different basis.
-
For Q3 FY26, ScanX cites EBITDA of INR 52 crore and Sharekhan cites INR 44.6 crore (16.4% margin). This is an unresolved source discrepancy, possibly due to treatment of other items.
Margin profile
Revenue CAGR FY2022–FY2026: about 18.2% (INR 554.8 crore to INR 1,081.2 crore over four years). The three-year CAGR from FY2023 to FY2026 is about 13.6%.
Commentary:
Volume reset (FY22–FY23): revenue grew 33–36% a year as volumes recovered from COVID and Gurugram beds expanded (363 to 427 per CARE).
Capacity absorption (FY24–FY25): growth slowed to 19% and then 6.6% as the second and third towers came on stream and utilisation lagged. FY25's slow top line coincides with occupancy around 61–64%.
Operating leverage (FY26–Q1 FY27): EBIT margin widened about 450 bp over four years, to 13.1%. Q1 FY27 operating margin excluding other income was 19.64%, the highest in at least eight quarters (MarketsMojo).
Below-the-line support: FY25 PAT growth of 68% was helped by interest income of about INR 26.6 crore on IFC CCD proceeds, up from INR 4.3 crore in FY24. Other income has since declined as these funds are spent on expansion (Q1 FY27 commentary).
Balance sheet (consolidated, INR crore)
Notes:
-
FY22–FY25 borrowings are standalone (Arihant/CMOTS); FY26 is consolidated (MarketsMojo; integrated filing).
-
FY26 borrowings split into non-current INR 189.95 crore and current INR 36.91 crore (integrated filing, 31 Mar 2026).
-
The aggregator's "short-term investments" excludes bank deposits. The FY26 integrated filing shows other bank balances of INR 172.74 crore in addition to cash of INR 33.41 crore. Including these, FY26 net borrowings were only about INR 21 crore. The Company separately reported outstanding borrowing of INR 225.70 crore as of 31 Mar 2026 in its "not a large corporate" disclosure (29 Apr 2026).
-
Goodwill is not separately disclosed in retrieved data and is presumed nil or immaterial.
-
FY25 equity jumps because the INR 330 crore IFC CCDs are classified within equity, being compulsorily convertible. They converted to 1.89 crore shares in Nov 2025.
Cash flow (consolidated, INR crore)
Notes:
-
Source is StockAnalysis, converted from INR million.
-
Capex is derived as operating cash flow minus FCF.
-
FY25 debt issued includes the IFC CCDs.
-
FY26 investing cash flow includes INR 134.9 crore that the aggregator classifies as "cash acquisitions". It most likely represents capital advances or security deposits for the MSA/long-term-agreement hospitals; other long-term assets rose to about INR 227.6 crore.
-
Dividends paid were roughly INR 6 crore a year (derived as about 134–138 million shares × INR 0.45).
-
No share buybacks were made in the period.
Ratios
Notes:
-
Ratios are computed by the analyst from the tables above. FY22 average equity uses the FY21 standalone figure (INR 321.6 crore).
-
Net debt/EBITDA for FY26 is about 1.05x on the aggregator basis (INR 228.2 crore / INR 218.0 crore). Including bank deposits it is about 0.1x.
-
ROIC is not publicly disclosed. Screener reports ROCE of 14.6–14.9% (2026 snapshots) and ROE of 12.9%.
Ratio commentary:
Balance sheet repair: the IFC CCD (FY25) and its conversion (FY26) took gearing from 0.71x to 0.28x. CareEdge cited this strengthening in its 2024 upgrade.
Coverage: interest coverage has recovered to 5.8x, and quarterly interest fell from INR 7.38 crore to INR 6.46 crore between Q1 FY26 and Q1 FY27.
Returns: ROE is stuck at 11–13% because equity rose ahead of earnings. The three-year average ROE of 11.7% is flagged by Screener as a weakness.
Working capital: the hospital business runs a modest cash cycle of about 36–47 days. Receivables from government schemes and international facilitators are the main drag.
Quarterly run-rate (consolidated, INR crore)
Sources: Fyers quarterly data; Q2 FY26 (revenue INR 27,470 lakh, PAT INR 3,000 lakh); Q3 FY26 release (PAT INR 2,223 lakh, +7.9%); Q4 FY26 release (PAT INR 3,028 lakh, +32.1%); Q1 FY27 release (PAT INR 31.44 crore, +48.3%). Q1 FY27 PBT was INR 42.63 crore (+43.2%) and other income INR 5.37 crore.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | Q3FY25 | Q4FY25 | Q1FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|
Consolidated revenue (INR Cr) | 232.4 | 239.9 | 255.0 | 272.4 | 279.2 | 287.3 |
Artemis Hospital Gurugram revenue (INR Cr) | 217.1 | 225.2 | 241.3 | 260.9 | 267.5 | 278.5 |
Gurugram share of consolidated (%) | 93.4 | 93.9 | 94.6 | 95.8 | 95.8 | 96.9 |
Results by Segment and Segment Margins & Growth (%)
| Metric | Q4FY25 | Q1FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
Consolidated EBITDA (INR Cr) | 48.2 | 48.3 | 59.4 | 61.8 |
Gurugram EBITDA (INR Cr) | 48.1 | 49.5 | 58.0 | 61.6 |
Consolidated EBITDA margin (%) | 20.1 | 18.9 | 21.3 | 21.5 |
Business Units
| Unit | What it contains | Financial disclosure |
|---|---|---|
Artemis Cardicare Pvt Ltd (65% subsidiary; JV with Philips) | Artemis Cardiac Care centres (seven centres in Apr 2024, mainly Tier-2/3 cath-lab-led cardiac units; Chennai closed Jan 2025) | Not publicly disclosed separately |
Artemis Lite | Neighbourhood multi-specialty hospitals (NFC Delhi; Sector 82A Gurugram per Artemis profile listings) | — |
Daffodils by Artemis | Women & child hospitals (Sector 40 Gurugram; East of Kailash, Delhi) | — |
Artemis Shanti Hospital, Raipur | 300+ bed super-specialty (some summaries cite 200 beds added under a long-term agreement), opened 9 Jul 2026 | Gestation; costs tracked separately per management |
Mauritius (Curepipe 80 beds; Cascavelle 110 beds announced) | Operations/management arrangement | — |
VIMHANS Artemis Hospital (South Delhi) | 650+ bed MSA; commissioning targeted for FY29 | Pre-operational |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 554.8 | 737.4 | 878.6 | 936.9 | 1,081.2 |
Revenue growth YoY (%) | 35.9 | 32.9 | 19.1 | 6.6 | 15.4 |
Total income incl. other income (INR Cr) | 558.7 | 744.8 | 885.9 | 969.9 | 1,111.1 |
Gross profit, aggregator basis (INR Cr) | 91.9 | 138.1 | 177.6 | 197.7 | 237.7 |
Operating income EBIT ex other income (INR Cr) | 46.5 | 63.9 | 93.5 | 108.1 | 142.1 |
Interest expense (INR Cr) | 9.4 | 17.3 | 27.8 | 28.5 | 24.5 |
Profit before tax, consolidated (INR Cr) | — | — | 68.5 | 107.7 | 139.2 |
Profit before tax, standalone (INR Cr) | 39 | 53 | 68.0 | 109.3 | — |
Net profit (INR Cr) | 31.8 | 38.6 | 49.1 | 82.6 | 103.6 |
EPS derived, net profit / period-end shares (INR) | 2.40 | 2.88 | 3.62 | 6.00 | 6.55 |
Dividend per share (INR) | — | 0.45 | 0.45 | 0.45 | 0.45 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) — Operating profit, standalone, Screener
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating profit, standalone, Screener (INR Cr) | 68 | 94 | 128 | 150 | — |
EBITDA, consolidated, Company (INR Cr) | — | — | — | — | 218.0 |
EBITDA margin, consolidated (%) | — | — | — | — | 20.2 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin, aggregator basis (%) | 16.6 | 18.7 | 20.2 | 21.1 | 22.0 |
Operating EBIT margin (%) | 8.4 | 8.7 | 10.6 | 11.5 | 13.1 |
Net margin (%) | 5.7 | 5.2 | 5.6 | 8.8 | 9.6 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 709.7 | 905.0 | 971.5 | 1,357.4 | 1,428.7 |
Cash and cash equivalents (INR Cr) | 15.7 | 22.9 | 14.6 | 41.6 | 33.4 |
Cash plus short-term investments, aggregator (INR Cr) | 27.7 | 50.9 | 14.6 | 41.6 | 33.4 |
Total debt incl. lease liabilities, aggregator (INR Cr) | 201.2 | 285.9 | 320.3 | 290.3 | 261.6 |
Borrowings excl. leases (INR Cr) | 190.4 | 268.2 | 304.9 | 280.5 | 226.9 |
Net debt, aggregator basis (INR Cr) | 173.5 | 234.9 | 305.7 | 248.7 | 228.2 |
Shareholders' equity (INR Cr) | 359.4 | 403.1 | 448.4 | 837.7 | 934.7 |
Other intangible assets (INR Cr) | 4.3 | 7.5 | 7.0 | 10.1 | 12.3 |
Total current assets (INR Cr) | 127.0 | 170.4 | 180.1 | 535.1 | 366.8 |
Total current liabilities (INR Cr) | 138.2 | 205.8 | 184.6 | 216.1 | 210.8 |
Net working capital (INR Cr) | -11.2 | -35.4 | -4.5 | 319.0 | 156.0 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 59.5 | 127.2 | 108.9 | 155.7 | 131.9 |
Capital expenditure derived (INR Cr) | 108.9 | 146.5 | 72.6 | 93.1 | 104.9 |
Free cash flow (INR Cr) | -49.4 | -19.3 | 36.3 | 62.6 | 27.0 |
Free cash flow margin (%) | -8.9 | -2.6 | 4.1 | 6.7 | 2.5 |
Cash interest paid (INR Cr) | 11.1 | 20.1 | 33.0 | 31.1 | 27.2 |
Debt issued (INR Cr) | 79.1 | 82.8 | 45.3 | 350.8 | 64.2 |
Debt repaid (INR Cr) | 24.6 | 27.5 | 37.2 | 40.3 | 80.9 |
Investing cash flow (INR Cr) | -107.2 | -158.2 | -88.1 | -393.2 | -90.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 9.3 | 10.1 | 11.5 | 12.8 | 11.7 |
ROA on period-end assets (%) | 4.5 | 4.3 | 5.1 | 6.1 | 7.3 |
Current ratio (x) | 0.92 | 0.83 | 0.98 | 2.48 | 1.74 |
Debt to equity incl. leases (x) | 0.56 | 0.71 | 0.71 | 0.35 | 0.28 |
Interest coverage EBIT / interest (x) | 5.0 | 3.7 | 3.4 | 3.8 | 5.8 |
Asset turnover, revenue / period-end assets (x) | 0.78 | 0.81 | 0.90 | 0.69 | 0.76 |
Cash conversion cycle, standalone Screener (days) | 47 | 43 | 36 | 37 | — |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 255.0 | 274.7 | 272.4 | 279.2 | 287.3 |
Net profit (INR Cr) | 21.3 | 30.0 | 22.2 | 30.3 | 31.4 |
Net margin (%) | 8.3 | 10.9 | 8.2 | 10.8 | 10.9 |
Revenue by Region and Revenue by Region (%)
| Metric | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
International patient revenue (INR Cr) | — | 82.3 | 76.5 |
International share of Gurugram revenue (%) | 34 | 30.8 | 27.5 |
International revenue growth YoY (%) | 34.9 | 13.5 | 8.6 |
Payor Details
| Payor | Share of revenue (%) |
|---|---|
International patients | 27 |
Insured patients | 33 |
Domestic cash patients | 23 |
Government schemes | 17 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Price (12 Oct 2026) | INR 311.45 | Tickertape |
Market cap (12 Oct 2026) | INR 4,958 crore | Tickertape / Kotak Neo |
52-week high / low | INR 378.80 / INR 203.35 | Kotak Neo |
1-year return | About +30% (as of 12 Oct 2026) | Kotak Neo |
Calendar 2026 YTD | About +40% at 25 Sep 2026, versus Sensex about –12% | Analytics Insight |
Share Price
| Metric | 02-Mar-2026 | 30-Mar-2026 | 20-Apr-2026 | 18-Jun-2026 | 31-Jul-2026 | 22-Aug-2026 | 25-Sep-2026 | 12-Oct-2026 |
|---|---|---|---|---|---|---|---|---|
Closing or quoted price (INR) | 229.98 | 205.51 | 229.62 | 259.15 | 299.00 | 326.10 | 378.40 | 311.45 |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
P/E (TTM) | About 43.6x | TTM PAT of about INR 113.7 crore (FY26 INR 103.6 crore + Q1 FY27 INR 31.4 crore – Q1 FY26 INR 21.3 crore) |
P/B | About 5.3x | FY26 equity INR 934.7 crore |
EV/EBITDA (TTM) | About 21.5x | EV about INR 4,979 crore (market cap + borrowings INR 226.9 crore – cash and bank INR 206.1 crore); TTM EBITDA about INR 231.5 crore |
EV/Sales (TTM) | About 4.5x | TTM revenue about INR 1,113.5 crore |
Aggregator P/E | 42–45x (Jul–Aug 2026) | Angel One; Torus; ICICI Direct |
Broker / Aggregate Details
| Broker / aggregate | Rating | Target (INR) | Date |
|---|---|---|---|
InCred Equities | Initiation (positive) | 437 | Sep 2026 |
Sharekhan | Hold | 250 | 19 Feb 2026 |
INDmoney aggregate (3 analysts) | — | 364 average | Dated snapshot |
Sharpely consensus | Buy (100% buy or strong buy) | 328 | Jul 2026 |
Capital Markets
| Item | Detail |
|---|---|
Dividend policy and history | Final dividend of INR 0.45 per share for FY26 (record date 10 Jul 2026); flat in recent years per aggregator; yield about 0.15–0.17% |
Buybacks | None authorised |
Credit ratings | CareEdge: CARE A; Stable (long-term bank facilities INR 427.90 crore) and CARE A; Stable / CARE A2+ (INR 45 crore long-term/short-term), reaffirmed 12 Aug 2025. No Moody's, S&P or Fitch ratings. |
Debt maturity profile | Borrowings of INR 226.9 crore at 31 Mar 2026: INR 36.9 crore current (due within 12 months) and INR 190.0 crore non-current. The detailed maturity ladder is not publicly disclosed in retrieved sources. |
Analyst Ratings & Targets
| Date | Rating |
|---|---|
Jul 2020 | CARE A-; Stable |
Sep 2022 | CARE A-; Stable |
Aug 2023 | CARE A-; Stable |
Sep 2024 | CARE A; Stable (upgrade) |
Aug 2025 | CARE A; Stable |
Analyst Conclusions
Management guidance recap
-
Gurugram occupancy of about 70% by Q2 FY27 and 68–70% for FY27.
-
ARPOB growth of 4–6% a year.
-
Continued absolute EBITDA expansion in FY27.
-
Raipur breakeven within 18–24 months of its July 2026 launch.
-
VIMHANS phase 1 (~450 beds) by FY29.
-
Group capacity of 2,000–2,300 beds by 2029, funded partly by up to INR 700 crore of new equity.
Consensus
A formal consensus for FY27/FY28 revenue and EPS was not publicly available in retrieved sources. Sharekhan's November 2025 model projected FY27 sales of about INR 1,488 crore; that projection assumed earlier Raipur commissioning and should be treated as stale.
Bull case
-
Utilisation-driven operating leverage. Each point of Gurugram occupancy on about 544 operational beds at an ARPOB of about INR 85,700 adds roughly INR 17 crore of annual revenue at high incremental margin. Q1 FY27 shows the effect: EBITDA +27.9% on revenue +12.7%.
-
Cheap capacity. 100–125 FAR-bonus beds at no extra land cost, plus MSA hospitals (VIMHANS, Raipur), can grow beds far faster than the capital base, lifting ROE from the current 11–13%.
-
Valuation gap. At about 44x TTM P/E and about 21x EV/EBITDA, Artemis trades well below the 60–70x P/E of NCR peers Max, Fortis and Medanta. InCred's INR 437 target implies about 40% upside.
Bear case
-
Concentration plus competition. About 97% of revenue comes from one hospital, in a micro-market where Medanta and Fortis are adding capacity. Any share loss or doctor attrition hits the whole P&L.
-
Dilution and gestation. Up to INR 700 crore of equity (about 14% of market cap), Raipur losses for 18–24 months and falling treasury income could stall EPS growth in FY27–FY28 even as EBITDA grows.
-
International-patient fragility. The flagship's highest-margin channel slowed from +34.9% to +8.6% YoY within two quarters on geopolitics. The 44.5% promoter pledge adds overhang risk.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q2 FY27 results | Early Nov 2026 (window closed from 1 Oct) | Whether occupancy reached 70%; first-quarter Raipur losses; international revenue trend |
| INR 700 crore QIP / preferential pricing | H2 FY27 | Issue price versus market; investor quality; use of proceeds |
| Commissioning of 100 incremental Gurugram beds | Once occupancy is at least 70% | Timing and ramp |
| Raipur ramp-up | FY27–FY28 | Occupancy, ARPOB, EBITDA loss trajectory |
| VIMHANS construction | Started Apr–May 2026 | Milestones toward FY29 |
| New MSA or acquisition announcements | FY27 | Deal terms and capital intensity |
| CGST show-cause outcome | FY27 | Final liability |
| CareEdge annual surveillance | About Aug 2027 | Rating direction post-raise |
| Promoter pledge changes | Quarterly shareholding | Release or increase |
Analyst verdict
Artemis Medicare enters FY27 with the strongest operating momentum in its listed history. Consolidated revenue compounded at about 18% from FY22 to FY26, reaching INR 1,081 crore. Net profit more than tripled from INR 31.8 crore to INR 103.6 crore. Q1 FY27 delivered a record operating margin of about 19.6% (excluding other income) on rising occupancy (65.7%) and pricing (ARPOB INR 85,690). The balance sheet that once constrained growth has been repaired. The IFC CCD conversion and steady cash generation cut debt/equity to about 0.28x, and the CareEdge upgrade to A captured the improvement.
The open question is whether a single, high-quality hospital can become a scalable network without sacrificing its returns profile. The asset-light MSA approach (Raipur, VIMHANS) and the FAR-led brownfield are sensible answers in principle. They let Artemis add beds with far less capital per bed than a greenfield build. However, the model also introduces new risks: partner dependence, gestation losses at Raipur and dilution from the INR 700 crore raise. Disclosure on these arrangements has so far been thin. Meanwhile, the flagship's most profitable channel, international patients, has decelerated sharply on West Asia disruption. Competition in Gurugram intensifies as Medanta and others add beds.
At about 44x trailing earnings and about 21x EV/EBITDA, the market is pricing in a successful transition, though at a meaningful discount to large NCR peers. We view the risk-reward as constructive but execution-dependent. Three things would validate the bull case over the next 12 months: occupancy crossing 70% (unlocking the deferred 100 beds), QIP pricing at or above about INR 300 with quality long-only participation, and Raipur losses tracking the 18–24-month breakeven guidance. Failure on any two would likely push the stock back toward the Sharekhan-style valuation anchor of about 26x forward earnings. Investors should also track the 44.5% promoter pledge closely.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation (FY26) |
|---|---|---|---|---|
Onkar S. Kanwar | Chairman (promoter) | Founder-promoter since 2004 | Chairman of Apollo Tyres Ltd; heads the promoter group holding through Constructive Finance Pvt Ltd | Not publicly disclosed in retrieved sources |
Dr. Devlina Chakravarty | Managing Director (MD & CEO, Artemis Hospitals Group) | MD/Executive Director since 2 Feb 2015 (CEO from Jan 2014 per Simply Wall St); re-appointment approved by the Board on 14 Nov 2024 and by postal ballot on 26 Dec 2024 | Physician (MD, DNB, DMRD – Radiology); about 2.5% direct shareholding per a dated Simply Wall St snapshot | Not publicly disclosed in retrieved sources |
Poonam Makkar | Company Secretary & Compliance Officer | — | — | — |
Rudra Narayan Acharjee | Head – Investor Relations, M&A and Organisation Growth Strategy (Senior Management) | From 18 Sep 2025 | — | — |
Dr. Sandeep G. Attawar | Clinical lead, Heart & Lung Transplant Centre | 2,026 | Decades of experience setting up thoracic transplant programmes in India | Not applicable |
“—” = not publicly disclosed.
Governance Overview
| Attribute | Detail | Source |
|---|---|---|
Board size | 10 directors (FY26), down from 11 at 31 Mar 2025 | BRSR FY26; FY25 Directors' Report |
Composition at 31 Mar 2025 | 1 Executive, 4 Non-Executive, 6 Independent (including 2 women) | FY25 Directors' Report |
Gender | 3 of 10 directors are women (30%) | BRSR FY26 |
Chair/CEO separation | Yes: Non-Executive promoter Chairman (Onkar Kanwar) and a separate MD (Dr. Chakravarty) | Filings |
Recent change | Independent Director Sanjib Sen (DIN 07088442) ceased on completing his tenure, 2 Aug 2026 | Exchange disclosure, 3 Aug 2026 |
Committees | Statutory committees under SEBI LODR (Audit, Nomination & Remuneration, Stakeholders' Relationship, CSR, Risk Management); a Board committee reviews BRSR/NGRBC principles | — |
IFC rights | Policy Rights Agreement with IFC (2024) gives IFC certain special rights, approved at the 3 May 2024 EGM | Digital Health News |
Internal auditor | Prateek Rastogi, CA, appointed from 12 Nov 2025 | Board outcome, 11 Nov 2025 |
Secretarial auditor | Ankit Tiwari & Co. (per 22nd AGM proceedings) | NSE AGM disclosure |
Shareholding Trend
| Holder category | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
Promoter and promoter group (%) | 58.38 | 58.39 | 58.39 |
Institutions (%) | 21.53 | 21.24 | 20.84 |
Non-institutions (%) | 20.07 | 20.36 | 20.76 |
Major Shareholders
| Holder | Stake (%) | Type | Source |
|---|---|---|---|
Constructive Finance Private Limited | 58.38 | Promoter holding company | MarketsMojo, Jun 2026 |
International Finance Corporation | 11.98 | Multilateral / FPI | MarketsMojo, Jun 2026 |
Body corporate where Central/State Government is promoter (3,000,000 shares; name not shown) | 1.90 | Institutional | Shareholding pattern, Mar 2026 |
AMSL Unclaimed Suspense Account | 1.48 | Legacy unclaimed shares | Shareholding pattern, Mar 2026 |
Mutual funds (5 schemes) | 1.30 (Jun 2026); 0.92 (Oct 2026 per Kotak) | DII | MarketsMojo; Kotak Neo |
Other FIIs (21 FIIs in aggregate including IFC) | 12.29 total FII | FPI | MarketsMojo |
Onkar Kanwar (individual) | 0.01 | Promoter individual | Shareholding pattern |
Individual investors | 12.79 | Retail | MarketsMojo |
Competitive Landscape
Key Competitors
| Competitor | Listed entity | Overlap with Artemis | Relative positioning |
|---|---|---|---|
Medanta – The Medicity, Gurugram | Global Health Ltd (MEDANTA) | Direct; same city, quaternary, international patients | Much larger scale; capacity grew 20% in FY26 |
Fortis Memorial Research Institute, Gurugram | Fortis Healthcare (FORTIS) | Direct; Gurugram quaternary and transplants | National chain scale |
Max Super Speciality (Saket and Gurugram) | Max Healthcare (MAXHEALTH) | Direct in NCR; oncology and cardiac | Highest NCR scale and margins |
Apollo Indraprastha, New Delhi | Apollo Hospitals (APOLLOHOSP) | NCR tertiary; international patients | Largest listed chain |
Manipal Hospitals (Dwarka, Gurugram) | Manipal Health (listing status per aggregator: MANIPALHOS) | NCR multi-specialty | Pan-India scale |
Narayana Health, Gurugram | Narayana Hrudayalaya (NH) | Cardiac, Gurugram | Cost-leadership model |
Paras Health, Gurugram | Unlisted | Gurugram tertiary | Regional |
CK Birla, Marengo Asia, W Pratiksha (Gurugram) | Unlisted | Gurugram multi-specialty | Regional |
Sir Ganga Ram, BLK-Max, Indian Spinal Injuries Centre | Trust / partly listed | Delhi tertiary | Referral competition |
Yatharth Hospital, Park Hospital (NCR) | Listed small caps | NCR mid-market | Lower ARPOB |
Raipur: Ramkrishna CARE, NH MMI Raipur, AIIMS Raipur, Shri Balaji | Mixed | Raipur tertiary | Incumbents Artemis must displace |
Medical-tourism peers: Medanta, Fortis, Apollo, Max | Listed | International patient share | Artemis' 27–34% mix is among the highest in its peer set |
Peer Comparison FY2026
| Company | Market cap (INR Cr) | P/E (x) | Annual PAT (INR Cr) |
|---|---|---|---|
Apollo Hospitals | 126,300 | 60.5 | 1,942 |
Max Healthcare | 96,763 | 66.4 | 1,442 |
Fortis Healthcare | 68,901 | 65.8 | 1,042 |
Global Health (Medanta) | 38,149 | 68.6 | 556 |
Narayana Hrudayalaya | 38,439 | 47.1 | 806 |
Artemis Medicare | 5,063 | 44.6 | 104 |



